Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 SEP 14 ... that data from the Company's third generation recombinant protective antigen (rPA) anthrax vaccine program and its Valortim anthrax anti-toxin program were presented at the Bacillus - ACT ...
2009 OCT 12 ... of Health and Human Services as one of the most serious biological weapons, along with anthrax and tularemia. The Johns Hopkins Working Group on Civilian Biodefense notes ... a biological weapon is of great concern."(1) Unlike anthrax, there is no FDA-approved vaccine available to protect against plague, and the only antibiotic treatments currently ...
2009 OCT 5 ... of at least one other protein subunit vaccine, which is currently expected to be an anthrax vaccine. This could lead to new subunit vaccines that would bypass current cold chain ...
2009 NOV 16 ... Secured a $4.9 million development grant from NIAID to fund development of an advanced anthrax vaccine candidate, dmPA7909, one of the Company's next generation...
2009 SEP 21 ... vaccines in the future," Vance added. New vaccines for cancer, salmonella, anthrax Portnoy's work has already led to two promising Listeria-based vaccines. ... attenuated vaccines don't always work. It also suggests ways to engineer an attenuated vaccine to make it as potent as a live vaccine but as safe as a killed vaccine. ...
2009 NOV 1 ... vaccinated against seasonal and pandemic influenza, hepatitis B, RSV, HIV, pneumococcal, anthrax, smallpox and other diseases. The company's NanoStat™ adjuvant platform ... Allergy and Infectious Diseases, a Division of The National Institute of Health, to fund vaccine research associated with "Innate Immune Receptors and Adjuvant Discovery." NanoBio is ...
2009 OCT 12 ... National Institutes of Health, to further the development of one of Emergent's advanced anthrax vaccine candidates known as dmPA7909. The novel vaccine candidate is designed to have ...
2009 SEP 7 ... prepared." Passport Health (www.passporthealthusa.com) has provided anthrax and smallpox vaccination training and has worked with the U.S. military, federal postal ... calls with the CDC and will be ready to assist with the administration of the H1N1 vaccine and antivirals as per CDC directives." Firestorm (www.firestorm.com) ...
Subject: Passport Health USA and Firestorm Solutions LLC
2009 OCT 19 ... "PharmAthene is developing a second generation recombinant protective antigen (rPA) anthrax vaccine called SparVax™ to protect civilians and the military and to advance our company ...
2009 AUG 24 ... related to the SparVax™, RypVax™ and the Company's third generation rPA anthrax vaccine programs. General and administrative expenses for the Company were $4.4 ...
2009 NOV 23 ... extent, of activities related to RypVax™ and the Company's third generation rPA anthrax vaccine program. General and administrative expenses were $6.2 million and $4.8 ...
2009 NOV 23 ... are being vaccinated during child-bearing years, including vaccination with BioThrax (Anthrax Vaccine Adsorbed, or AVA). As only a limited number of studies exist in humans that have ...
2009 NOV 23 ... "Anthrax toxin neutralization assays are used to measure functional antibody levels elicited by ... the anthrax toxin neutralization assay," scientists writing in the journal Clinical and Vaccine Immunology report. "Significantly more Fc gamma receptor-dependent ...
2009 NOV 9 ... (PA), the binding subunit of anthrax toxin, is the major component in the current anthrax vaccine, but the fine antigenic structure of PA is not well defined. To identify linear ...
2009 NOV 2 ... the test of time." "For decades, scholars have reported that the human anthrax vaccine field trials conducted in the 1950s by Brachman and his colleagues were single-blind ...
2009 SEP 7 ... microbes: the virus that causes Ebola hemorrhagic fever and the bacterium that causes anthrax. Taken together, the results suggest a common host restriction factor and a promising ... gastrointestinal, and inhalational-depending upon the route of exposure. A licensed vaccine is available, and is protective if administered before exposure. Inhalational anthrax is ...
Subject: US Army Medical Research Institute of Infectious Diseases
2009 NOV 2 ... Although recombinant PA (rPA) is likely to be an important constituent of any future anthrax vaccine, evaluation of the efficacies of the various candidate rPA vaccines is currently ...
2009 AUG 17 ... a critical tool for the rapid production of vaccines against influenza, avian influenza, anthrax, and Alzheimer's disease utilizing molecular techniques and state of the art cell ... Vaxin Inc. an emerging vaccine company, recently announced promising initial study data for its lead, intranasal ...
2009 NOV 9 ... study from the intelligence community projected that a two-to-four pound release of anthrax spores from a crop duster plane could kill more Americans than died in World War II. ... flexibility and authority to contain the pandemic. But the current shortage of H1N1 vaccine underscores the severe lack of U.S. preparedness in responding to pandemics, whether ...
Subject: Commission on the Prevention of Weapons of Mass Destruction Proliferation and Terrorism
